3D Medicines Past Earnings Performance
Past criteria checks 0/6
3D Medicines has been growing earnings at an average annual rate of 6.4%, while the Biotechs industry saw earnings growing at 11.7% annually. Revenues have been growing at an average rate of 62.1% per year.
Key information
6.4%
Earnings growth rate
40.1%
EPS growth rate
| Biotechs Industry Growth | 11.0% |
| Revenue growth rate | 62.1% |
| Return on equity | -64.6% |
| Net Margin | -82.6% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How 3D Medicines makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 635 | -525 | 596 | 425 |
| 30 Jun 23 | 713 | -894 | 614 | 329 |
| 31 Mar 23 | 640 | -959 | 557 | 340 |
| 31 Dec 22 | 567 | -1,024 | 501 | 351 |
| 31 Dec 21 | 60 | -1,434 | 194 | 371 |
Quality Earnings: 1244 is currently unprofitable.
Growing Profit Margin: 1244 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if 1244's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare 1244's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 1244 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (22.1%).
Return on Equity
High ROE: 1244 has a negative Return on Equity (-64.61%), as it is currently unprofitable.